Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
) }" T; ?( J. r& ?NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
- e: v: H& |6 @" R6 \7 X! ?+ Author Affiliations0 a7 S+ K2 C# ` ~3 T' b
) I" n& l0 `! q& R$ T, w5 [ I: P
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 8 _ }) k7 O$ O8 m7 q+ F) `
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& P9 Y' u% Y* v8 M' w# W+ H3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 x* U4 j8 s1 `
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) Q% |( y# A- C! i( d. f
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan , b5 Y/ ^* n5 F, k: n7 q" y) C
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
+ X3 y1 C: u. I! F. L( v7Kinki University School of Medicine, Osaka 589-8511, Japan
. _6 X9 m7 w6 Q2 W8Izumi Municipal Hospital, Osaka 594-0071, Japan ( W+ @; M8 d0 k$ ?( D: {8 C* a
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
% T/ T7 X `' |" ~9 DCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
- S/ B$ o. G+ T/ A7 [- ]. h1 AAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. . R5 D o! H) n4 A9 _
/ M$ A# w# ^# F
|